AR-driven prostate cancer models are preferentially sensitive to BRD4 inhibition, since BRD4 and AR co-localise at target loci, including super-enhancers, to drive AR-mediated gene transcription [[16], [147]]. The gene discussed is BRD4; the disease is Familial prostate cancer.